The Development of selective and potent Kv1.3 ion channel blockers for the treatment of multiple sclerosis

开发用于治疗多发性硬化症的选择性强效 Kv1.3 离子通道阻滞剂

• 批准号: nhmrc : 406698
• 负责人: Dr Andrew Harvey
• 金额: $ 15.55万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-selective-potent-multiple-sclerosis/114846
• 关键词: Development; selective; potent; Kv1.3; ion

Building on the well-established path of developing drugs from Nature, the amplification of some unusual qualities of a naturally-occurring substance, khellinone, could lead to new treatments for autoimmune diseases such as multiple sclerosis and diabetes. Designed variants of khellinone are known to be very effective at preventing the destructive impact of the body's own T cells on the central nervous system that occurs in autoimmune disease.

在自然界开发药物的既定道路上，放大天然物质khellinone的一些不寻常的品质，可能会导致多发性硬化症和糖尿病等自身免疫性疾病的新疗法。已知凯力农的设计变体在预防自身免疫性疾病中发生的人体自身T细胞对中枢神经系统的破坏性影响方面非常有效。